A randomised controlled trial of dexmedetomidine for delirium in adults undergoing heart valve surgery. (16th February 2023)

• Record Type: Journal Article
• Authors: Wang, H.‐B.; Jia, Y.; Zhang, C.‐B.; Zhang, L.; Li, Y.‐N.; Ding, J.; Wu, X.; Zhang, Z.; Wang, J.‐H.; Wang, Y.; Yan, F.‐X.; Yuan, S.; Sessler, D. I.
• Is Part Of: Anaesthesia. Volume 78:Number 5(2023)
• Page Start: 571
• Page End: 576
• Publication Date: 2023-02-16
• Subjects: acute kidney injury -- anaesthesia -- cardiac surgery -- cardiopulmonary bypass -- dexmedetomidine -- postoperative delirium; Anesthesia -- Periodicals; 617.96
• DOI: 10.1111/anae.15983
• Languages: English
• ISSNs: 0003-2409

Abstract

Summary: Dexmedetomidine might reduce delirium after cardiac surgery. We allocated 326 participants to an infusion of dexmedetomidine at a rate of 0.6 μg kg −1 for 10 min and then at 0.4 μg.kg −1 .h −1 until the end of surgery; 326 control participants received comparable volumes of saline. We detected delirium in 98/652 (15%) participants during the first seven postoperative days: 47/326 after dexmedetomidine vs. 51/326 after placebo, p = 0.62, adjusted relative risk (95%CI) 0.86 (0.56–1.33), p = 0.51. Postoperative renal impairment (Kidney Disease Improving Global Outcomes stages 1, 2 and 3) was detected in 46, 9 and 2 participants after dexmedetomidine and 25, 7 and 4 control participants, p = 0.040. Intra‐operative dexmedetomidine infusion did not reduce the incidence of delirium after cardiac valve surgery but might impair renal function.